Endocrinology, Vol 135, 1316-1327, Copyright © 1994 by Endocrine Society

ARTICLES

Human insulin-like growth factor-binding protein-1 (hIGFBP-1) in transgenic mice: characterization and insights into the regulation of IGFBP-1 expression

Z Dai, Y Xing, CM Boney, DR Clemmons and AJ D'Ercole
Department of Pediatrics, University of North Carolina, Chapel Hill 27599.

Three hemizygous transgenic (Tg) mouse lines were generated with a fusion gene composed of the mouse metallothionein promoter (mMT-I) and a full-length human insulin-like growth factor binding protein-1 (hIGFBP-1) complementary DNA that was truncated in its 3'-untranslated region. Despite high serum hIGFBP-1 levels (120-2570 micrograms/liter) before puberty in two of these lines, no significant alterations were observed in somatic growth, nor were marked alterations noted in fasting or random serum glucose or in the response of young adult Tg mice to ip glucose. The transgene was expressed in a number of tissues from each line, but liver was a significant site of transgene expression in only one line. Unexpectedly, liver hIGFBP-1 messenger RNA (mRNA) expression in this line was regulated in fashion similar to the native liver IGFBP-1 mRNA: 1) its abundance waned with advancing postnatal age and became minimal in early adult life, despite continuous zinc supplementation to stimulate its transcription; and 2) fasting increased its abundance 3- to 4.3-fold. The decline in transgene expression with aging was not due to a deletion, rearrangement, or a change in the methylation of liver transgene DNA. Transcriptional mechanisms also were not likely to account for the observed regulation of the transgene mRNA, because liver expression of the mMT-I gene, which shares identical genomic 5'-regulatory elements with the transgene, was not similarly altered by aging or fasting. Because cycloheximide (CHX) treatment of cultured rat H4IIE cells has been shown to prolong IGFBP-1 mRNA half-life while decreasing its transcription, Tg mice were treated with CHX to test the possibility that instability of the liver transgene mRNA influenced its abundance. After CHX and under conditions of chronic zinc supplementation, liver transgene mRNA abundance increased in parallel with that of the native IGFBP-1 mRNA. Although CHX is known to activate mMT-I transcription by mechanisms involving the 5'-regulatory regions contained in the transgene, CHX-induced transcription only in part accounted for the increase in liver transgene mRNA, because CHX induced an earlier and greater increase in liver transgene mRNA than in mMT-I mRNA. Taken together, these data indicate that both transgene and native IGFBP-1 liver mRNA are regulated by factors that alter mRNA stability. The finding that native liver IGFBP-1 mRNA abundance is influenced by transgene expression further supports the concept that both mRNAs share some common mechanisms of regulation.(ABSTRACT TRUNCATED AT 400 WORDS)

This article has been cited by other articles:

				I. A. Murray and G. H. Perdew Omeprazole Stimulates the Induction of Human Insulin-Like Growth Factor Binding Protein-1 through Aryl Hydrocarbon Receptor Activation J. Pharmacol. Exp. Ther., March 1, 2008; 324(3): 1102 - 1110. [Abstract] [Full Text] [PDF]

				A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF]

				N. Ben Lagha, D. Seurin, Y. Le Bouc, M. Binoux, A. Berdal, P. Menuelle, and S. Babajko Insulin-Like Growth Factor Binding Protein (IGFBP-1) Involvement in Intrauterine Growth Retardation: Study on IGFBP-1 Overexpressing Transgenic Mice Endocrinology, October 1, 2006; 147(10): 4730 - 4737. [Abstract] [Full Text] [PDF]

				C. S. Watson, P. Bialek, M. Anzo, J. Khosravi, S.-P. Yee, and V. K. M. Han Elevated Circulating Insulin-Like Growth Factor Binding Protein-1 Is Sufficient to Cause Fetal Growth Restriction Endocrinology, March 1, 2006; 147(3): 1175 - 1186. [Abstract] [Full Text] [PDF]

				S. K. Frankel, B. M. Moats-Staats, C. D. Cool, M. W. Wynes, A. D. Stiles, and D. W. H. Riches Human insulin-like growth factor-IA expression in transgenic mice promotes adenomatous hyperplasia but not pulmonary fibrosis Am J Physiol Lung Cell Mol Physiol, May 1, 2005; 288(5): L805 - L812. [Abstract] [Full Text] [PDF]

				S. M. Firth and R. C. Baxter Cellular Actions of the Insulin-Like Growth Factor Binding Proteins Endocr. Rev., December 1, 2002; 23(6): 824 - 854. [Abstract] [Full Text] [PDF]

				J. V. Silha and L. J. Murphy Minireview: Insights from Insulin-Like Growth Factor Binding Protein Transgenic Mice Endocrinology, October 1, 2002; 143(10): 3711 - 3714. [Abstract] [Full Text] [PDF]

				A. Hoeflich, S. Nedbal, W. F. Blum, M. Erhard, H. Lahm, G. Brem, H. J. Kolb, R. Wanke, and E. Wolf Growth Inhibition in Giant Growth Hormone Transgenic Mice by Overexpression of Insulin-Like Growth Factor-Binding Protein-2 Endocrinology, May 1, 2001; 142(5): 1889 - 1898. [Abstract] [Full Text]

				K. Sakai, A. J. D'Ercole, L. J. Murphy, and D. R. Clemmons Physiological Differences in Insulin-Like Growth Factor Binding Protein-1 (IGFBP-1) Phosphorylation in IGFBP-1 Transgenic Mice Diabetes, January 1, 2001; 50(1): 32 - 38. [Abstract] [Full Text]

				S. C. van Buul-Offers, M. van Kleffens, J. G. Koster, D. J. Lindenbergh-Kortleve, M. G. Gresnigt, S. L. S. Drop, C. M. Hoogerbrugge, R. J. Bloemen, J. A. Koedam, and J. W. van Neck Human Insulin-Like Growth Factor (IGF) Binding Protein-1 Inhibits IGF-I-Stimulated Body Growth but Stimulates Growth of the Kidney in Snell Dwarf Mice Endocrinology, April 1, 2000; 141(4): 1493 - 1499. [Abstract] [Full Text] [PDF]

				M. R. SCHNEIDER, H. LAHM, M. WU, A. HOEFLICH, and E. WOLF Transgenic mouse models for studying the functions of insulin-like growth factor-binding proteins FASEB J, April 1, 2000; 14(5): 629 - 640. [Abstract] [Full Text]

				A. Barreca, M. Bozzola, A. Cesarone, P. H. Steenbergh, P. E. Holthuizen, F. Severi, G. Giordano, and F. Minuto Short Stature Associated with High Circulating Insulin-Like Growth Factor (IGF)-Binding Protein-1 and Low Circulating IGF-II: Effect of Growth Hormone Therapy J. Clin. Endocrinol. Metab., October 1, 1998; 83(10): 3534 - 3541. [Abstract] [Full Text]

				D.-S. Suh and M. M. Rechler Hepatocyte Nuclear Factor 1 and the Glucocorticoid Receptor Synergistically Activate Transcription of the Rat Insulin-like Growth Factor Binding Protein-1 Gene Mol. Endocrinol., November 1, 1997; 11(12): 1822 - 1831. [Abstract] [Full Text]

				E. Gay, D. Seurin, S. Babajko, S. Doublier, M. Cazillis, and M. Binoux Liver-Specific Expression of Human Insulin-Like Growth Factor Binding Protein-1 in Transgenic Mice: Repercussions on Reproduction, Ante- and Perinatal Mortality and Postnatal Growth Endocrinology, July 1, 1997; 138(7): 2937 - 2947. [Abstract] [Full Text] [PDF]

				D. L. Mortensen, W. B. Won, J. Siu, D. Reifsnyder, M. Gironella, T. Etcheverry, and R. G. Clark Insulin-Like Growth Factor Binding Protein-1 Induces Insulin Release in the Rat Endocrinology, May 1, 1997; 138(5): 2073 - 2080. [Abstract] [Full Text] [PDF]

				R. Clark The Somatogenic Hormones and Insulin-Like Growth Factor-1: Stimulators of Lymphopoiesis and Immune Function Endocr. Rev., April 1, 1997; 18(2): 157 - 179. [Abstract] [Full Text]

				I. Ueki, G. T. Ooi, M. L. Tremblay, K. R. Hurst, L. A. Bach, and Y. R. Boisclair Inactivation of the acid labile subunit gene in mice results in mild retardation of postnatal growth despite profound disruptions in the circulating insulin-like growth factor system PNAS, June 6, 2000; 97(12): 6868 - 6873. [Abstract] [Full Text] [PDF]